EMA Public Hearings On Marketed Medicines To Start Next Year
Executive Summary
The European Medicines Agency is set to give EU citizens a voice in the safety evaluation of marketed medicines by holding its first public hearing next year, though no specific topic or date has been decided.
You may also be interested in...
Waiting For The Perfect Case: Why EMA Has Yet To Hold A Public Drug Safety Hearing
The European Medicines Agency has yet to use the power it has to hold public hearings on marketed medicines that raise safety concerns. It says it will do so only when the time is right.
Don't Let Sponsors Downplay Genuine Safety Concerns At Public Hearings, HAI Tells EMA
After the European Medicines Agency's pharmacovigilance committee (PRAC) finalized rules on how it would conduct public hearings to support the safety review of certain marketed medicines earlier this month1-3, medicines advocacy group Health Action International said that it welcomed the move, but warned that drug sponsors should not be allowed to downplay genuine safety concerns at such hearings.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.